The Extra-gastric Ettects of Chronic I Iclicobacter Pylori Infection on Some Metabolic Risk Factors in Dyspeptic Patients for Cormiary I lean Disease
|Full paper||Not Available|
Hyperlipidemia, thrombophilia and hyperhomocysteinemia were all known metabolic risk factors for coronary heart disease. The association between the extra-gastric effects of chronic helicobacter pylon (h.pylori) infection and these risk factors in dyspeptic patients needs to be clarified. Forty subjects were studied for determination of serum total cholesterol, triglycerides, very low density lipoprotein-cholesterol (VLDL-c), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c), plasma clotting factor VII, X, XII activities, fibrinogen concentration, antithrombin III (ATIII) activity as well as plasma total homocysteine. They were 26 males and 14 females. Their age ranged from 31 to 41 with mean value 35.8±2.6 years. They were categorized according to the concentration of h.pylori antibodies (IgG) into 15 patients who were seronegative and another 15 patients who were seropositive. These patients were compared with 10 healthy subjects, age and sex matched who served as controls. The results of this work showed that; serum lipid profile had no significant differences in seronegative and seropositive patients for h.pylori infection compared with the control group (p>0.05). Moreover, plasma clotting factor VII, X, XII had no significant changes while plasma fibrinogen concentration and total homocysteine were significantly higher in seropositive compared with both seronegative patients and the control group (p<0.05). Additionally, seropositivity correlated significantly with plasma fibrinogen concentration (r--0.76; p<0.05). We could conclude that, alteration of plasma fibrinogen and total homocysteine might be considered metabolic risk factors for coronary heart disease. However, estimation of these biomarkers in dyspeptic patients with chronic h.pylori infection were recommended to avoid the future risk of ischemic heart disease.